Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Sutro Biopharma (NASDAQ: STRO) announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 11:15 AM PT / 2:15 PM ET in San Francisco.
A live webcast will be accessible via the Events & Presentations page of the Investor Relations section at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Listing compliance | Positive | -6.9% | Nasdaq confirmed Sutro regained minimum bid price listing compliance. |
| Dec 16 | Equity inducements | Neutral | -1.2% | Inducement stock options and RSUs granted to new employees. |
| Dec 03 | Clinical trial start | Positive | +19.2% | First cohort dosed in Phase 1 trial of STRO-004 in solid tumors. |
| Dec 01 | Reverse stock split | Negative | -12.8% | 1-for-10 reverse split implemented to address Nasdaq bid price issue. |
| Nov 12 | R&D platform update | Positive | -0.3% | Virtual R&D Day highlighting next‑generation ADC platform and pipeline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News reactions have been mixed: positive clinical or compliance updates sometimes saw selling, while major clinical milestones drew strong buying.
Over the last few months, Sutro reported several structural and clinical milestones. A 1-for-10 reverse stock split and subsequent notice of regaining Nasdaq minimum bid compliance were followed by negative price reactions. In contrast, dosing the first cohort in the Phase 1 trial of STRO-004 on Dec 3, 2025 coincided with a 19.21% gain. R&D Day platform updates and inducement grants had limited impact. Today’s J.P. Morgan conference appearance fits into an ongoing effort to highlight its ADC pipeline to investors.
Key Terms
antibody drug conjugates medical
adcs medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 11:15 AM PT / 2:15 PM ET in San Francisco, CA.
A live webcast of the presentation will be accessible through the Events & Presentations page of the Investor Relations section of the Company’s website at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.
About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies. For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.
Investor Contact:
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
